French Michael T, McCollister Kathryn E, Cacciola John, Durell Jack, Stephens Raymond L
Department of Epidemiology and Public Health, University of Miami, Florida 33136, USA. mfrench@ miami.edu
Subst Abus. 2002 Mar;23(1):31-51. doi: 10.1080/08897070209511473.
A benefit-cost analysis of specialty residential treatment (Specialty) and standard residential treatment (Standard) was conducted on a sample of pregnant and parenting substance abusers from Arkansas. Economic benefits were derived from client self-reported information at treatment entry and at 6-month postdischarge with the use of an augmented version of the Addiction Severity Index (ASI). The average cost of treatment in Specialty programs was US dollars 8035 versus US dollars 1467 for Standard residential treatment. Average net benefits (benefit-cost ratios) were estimated to be US dollars 17144 (3.1) for Specialty and US dollars 8090 (6.5) for Standard. The main policy implication of this research is that investment in Specialty residential treatment for pregnant and parenting substance-abusing women appears to be economically justified, but future evaluations should analyze larger and more comparable samples to improve power and precision in the benefit-cost statistics.
对阿肯色州怀孕及育有子女的药物滥用者样本进行了专科住院治疗（专科治疗）和标准住院治疗（标准治疗）的效益成本分析。经济效益源自治疗开始时以及出院后6个月客户自我报告的信息，采用的是增强版的药物成瘾严重程度指数（ASI）。专科治疗项目的平均治疗成本为8035美元，而标准住院治疗为1467美元。估计专科治疗的平均净效益（效益成本比）为17144美元（3.1），标准治疗为8090美元（6.5）。这项研究的主要政策含义是，对怀孕及育有子女的药物滥用妇女进行专科住院治疗的投资在经济上似乎是合理的，但未来的评估应分析更大且更具可比性的样本，以提高效益成本统计的效力和精确性。
